Literature DB >> 2466127

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.

F Guadagni1, J Schlom, W W Johnston, C A Szpak, D Goldstein, R Smalley, J F Simpson, E C Borden, S Pestka, J W Greiner.   

Abstract

Freshly isolated cells from patients with pleural or peritoneal effusions cytologically diagnosed as adenocarcinoma (n = 43), malignant nonepithelial neoplasms (n = 10), and benign (n = 8) were analyzed for expression of constitutive levels of the tumor antigens TAG-72 [recognized by monoclonal antibody (MAb) B72.3] and carcinoembryonic antigen (CEA) (recognized by MAb COL-4) as well as the class I and class II major histocompatibility (MHC) antigens, and the ability of human interferons (Hu-IFNs) to enhance cell surface expression of those antigens as measured by MAb binding. Both type I and type II IFNs enhanced the expression of TAG-72 and CEA and altered the level of expression of the MHC antigens. Comparative studies of three different Hu-IFNs (IFN-alpha A, IFN-beta ser, and IFN-gamma) revealed that IFN-gamma was the most potent in augmenting either B72.3 or COL-4 binding. Unlike the IFN-gamma -mediated induction of the class II human leukocyte antigens, the change in tumor antigen expression consisted of enhanced constitutive antigen expression; de novo induction of either TAG-72 or CEA could not be achieved by either type I or type II IFN. Of 43 effusions isolated from different adenocarcinoma patients, 42 (97.7%) expressed either CEA or TAG-72, and treatment with Hu-IFN increased the level of expression of either antigen in 36 of 42 samples (85.7%). These studies demonstrate the augmentation of tumor-associated antigens on human carcinoma cells isolated from serous effusions by Hu-IFNs which may be used to enhance the targeting of conjugated MAbs to human carcinoma lesions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466127     DOI: 10.1093/jnci/81.7.502

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

1.  Quantification of transport and binding parameters using fluorescence recovery after photobleaching. Potential for in vivo applications.

Authors:  E N Kaufman; R K Jain
Journal:  Biophys J       Date:  1990-10       Impact factor: 4.033

Review 2.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 3.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

4.  A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Authors:  Megan C Duggan; Caroline Jochems; Renee N Donahue; Jacob Richards; Volodymyr Karpa; Elizabeth Foust; Bonnie Paul; Taylor Brooks; Susheela Tridandapani; Thomas Olencki; Xueliang Pan; Gregory B Lesinski; Jeffrey Schlom; William E Carson Iii
Journal:  Cancer Immunol Immunother       Date:  2016-08-31       Impact factor: 6.968

5.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

6.  Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.

Authors:  Hideaki Miyake; Isao Hara; Iori Sakai; Ken-ichi Harada; Taka-aki Inoue; Hiroshi Eto; Yoshizumi Takechi; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

7.  Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.

Authors:  F J Primus; T K Pendurthi; P Hutzell; S Kashmiri; D C Slavin; R Callahan; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Authors:  Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Authors:  D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.

Authors:  D M Mahvi; J A Madsen; P L Witt; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.